About ATTEST
What gets measured gets done.
We believe the metabolome is the next frontier for precision medicine. As the complete ensemble of small molecule metabolites, both endogenous and exogenous, the human metabolome reflects interaction of an individual's genome with their environment. It is where the rubber meets the road. There is a metabolic basis for most disease processes and an urgent need to provide better insight through high quality testing. For example over 50% of the 425 million people living with diabetes around the world are undiagnosed.
Point-of-care testing needs an accurate, portable, non-invasive technology for detection and quantitation of small molecule metabolites.
What we do
delight in creating well designed products 
Our Mission
provide innovative tools for increasing healthspan 
Our Vision
to enable healthy people to stay that way IP & Partnerships
US Provisional Patent Application, Number 62/731,576 Filing Date: 14 September 2018
METHOD AND SYSTEM FOR IN-VIVO, AND NON-INVASIVE MEASUREMENT OF METABOLITES
| Trademarks |
| ATTEST |
| MYSCANLAB |
| Canada |
| 19-Jun-2019, TMA1,028,513 |
| 19-Jun-2019, TMA1,028,500 |
| USA |
| 14-Jan-2020, Reg. No. 5,958,512 |
| 21-Jan-2020, Reg. No. 5,964,400 |
ATTEST gratefully acknowledges support through the Government of Canada Scientific Research & Experimental Development program.
Want to learn more about us? Please subscribe here.
ATTEST and myScanLab are trademarks of 10250929 Canada Inc registered in the US and Canada.
Value of Our Company
We are an early-stage startup actively seeking investors with experience in healthcare and the life sciences.
30
Years of Experience
5
Professional Advisors
97
Number of Patent Claims
$1.6B
Estimated TAM